Integra LifeSciences Holdings Corporation - Common Stock (IART)
26.14
-0.20 (-0.74%)
Integra LifeSciences is a global medical technology company that specializes in regenerative therapies and neurosurgical products
The company focuses on developing innovative solutions for healthcare providers, particularly in the areas of wound healing, neurosurgery, and reconstructive surgery. Integra's product portfolio includes a range of advanced biomaterials, surgical instruments, and specialized medical devices designed to enhance patient outcomes and support surgical procedures. By leveraging cutting-edge technologies, the company aims to address complex medical challenges and improve the quality of life for patients worldwide.
Integra LifeSciences' Q3 results show adjusted EPS of $0.41 and revenue at $380.83 million. Codman segment grows 1%, while Tissue Tech sees a 3.6% decline.
Kaskela Law LLC announces that it has commenced an investigation into Integra LifeSciences Holdings Corp. (NASDAQIART) (“Integra”) on behalf of the company’s long-term shareholders.
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of July 29 through Aug. 2.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Integra LifeSciences Holdings Corporation (NasdaqGS: IART).
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Integra LifeSciences Holdings Corporation (NasdaqGS: IART).
The stock market is poised to mark a third consecutive session of gains, with major indices all trading in the green during midday trading in New York on Monday, as traders continue to react positively to quarterly earnings and the Federal Reserve’s unexpectedly dovish stance
